NICE costing template for its guidance on ranibizumab for diabetic macular oedema (TA 274)

Source: NICE Area: News NICE has published a costing statement to accompany its guidance on the use of ranibizumab for treating visual impairment due to diabetic macular oedema (TA 274).   The costing report calculates that: "the annual cost associated with implementing this recommendation is estimated as £41,000 for a population of 100,000 based on the standard assumptions in the model once a steady state is reached. There are also anticipated to be non-recurrent costs from treating the prevalent population on implementation of the guideline of around £341,000. It is assumed that people with eligible eyes will start treatment immediately and will be treated over 3 years in line with the treatment regimen for ranibizumab."   Please see the links below for further details.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news